AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 16, 2021
29864_dirs_2021-02-16_b439a5c0-a2e7-4f8e-b5d9-1fd14dc1ced4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-11
Reporting Person: Sachdev Amit (EVP, Chief Patient Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-11 | Common Stock | S | 3860 | $210.43 | Disposed | 64142 | Direct |
| 2021-02-11 | Common Stock | S | 500 | $211.22 | Disposed | 63642 | Direct |
| 2021-02-11 | Common Stock | S | 100 | $211.98 | Disposed | 63542 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 882 | Indirect |
| Common Stock | 7368 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.43 (range $209.89 to $210.87).
F3: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.22 (range $210.92 to $211.87).